Literature DB >> 7713593

The role of cytokines in hemolytic transfusion reactions.

R D Davenport1.   

Abstract

Experimental evidence is accumulating to support a central role for cytokines in the pathophysiology of hemolytic transfusion reactions. The production of tumor necrosis factor, interleukin-8, and monocyte chemoattractant protein occurs in whole blood in response to ABO incompatible red cells, a model of acute hemolytic transfusion reactions. Peripheral blood mononuclear cells may produce interleukin-1 beta, tumor necrosis factor, interleukin-8, monocyte chemoattractant protein, and interleukin-1 receptor antagonist in response to IgG-coated red cells, a model of delayed hemolytic transfusion reactions. Cultured umbilical vein endothelial cells respond to conditioned plasma from ABO-incompatibility reactions by expressing the procoagulant tissue factor and the leukocyte adhesion molecules ELAM-1 and ICAM-1. These in vitro endothelial cell responses can be inhibited by neutralizing antibodies to tumor necrosis factor, suggesting that TNF may have a central role in intravascular coagulation and end-organ injury that may occur in acute hemolytic transfusion reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7713593     DOI: 10.3109/08820139509062782

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  2 in total

Review 1.  Duration of red blood cell storage and inflammatory marker generation.

Authors:  Caroline Sut; Sofiane Tariket; Ming Li Chou; Olivier Garraud; Sandrine Laradi; Hind Hamzeh-Cognasse; Jerard Seghatchian; Thierry Burnouf; Fabrice Cognasse
Journal:  Blood Transfus       Date:  2017-03       Impact factor: 3.443

2.  Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange.

Authors:  Burak Deveci; Rabin Saba; Husnu Altunay; Tayfur Toptas; George Kublashvilli; Ihsan Karadogan
Journal:  Transfus Med Hemother       Date:  2021-01-08       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.